Elevated peripheral blood glutamate levels in major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 14, Issue , 2018, Pages 945-953

  Inoshita, Masatoshi ^a   Umehara, Hidehiro ^a   Watanabe, Shin Ya ^a   Nakataki, Masahito ^a   Kinoshita, Makoto ^a   Tomioka, Yukiko ^a   Tajima, Atsushi ^b   Numata, Shusuke ^a   Ohmori, Tetsuro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Association study; Blood; Glutamate; Major depressive disorder; Meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; GLUTAMIC ACID;

AGE; AMINO ACID BLOOD LEVEL; ARTICLE; DRUG USE; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MASS SPECTROMETRY; PUBLISHING; SAMPLE SIZE; SYSTEMATIC REVIEW;

EID: 85045521393     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S159855     Document Type: Article

References (38)

1. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.
2. Dean J, Keshavan M. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101–111.
3. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31(6): 761–777.
4. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426–437.
5. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009;61(2):105–123.
6. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017; 16(7):472–486.
7. Mlyniec K. Zinc in the glutamatergic theory of depression. Curr Neuropharmacol. 2015;13(4):505–513.
8. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci. 2009;11(3):239–255.
9. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1558–1568.
10. Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav. 2012;100(4):688–704.
11. Küçükibrahimoğlu E, Saygin MZ, Calişkan M, et al. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol. 2009;65(6):571–577.
12. Maes M, Verkerk R, Vandoolaeghe E, et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998;97(4):302–308.
13. Romeo B, Choucha W, Fossati P, et al. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230(2):682–688.
14. Umehara H, Numata S, Watanabe SY, et al. Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Sci Rep. 2017;7(1):4855.
15. Altamura CA, Mauri MC, Ferrara A, et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993;150(11): 1731–1733.
16. Mauri MC, Ferrara A, Boscati L, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology. 1998;37(3):124–129.
17. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1155–1158.
18. Woo HI, Chun MR, Yang JS, et al. Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors. CNS Neurosci Ther. 2015;21(5):417–424.
19. Ogawa S, Koga N, Hattori K, et al. Plasma amino acid profile in major depressive disorder: analyses in two independent case-control sample sets. J Psychiatr Res. 2018;96:23–32.
20. Altamura C, Maes M, Dai J, et al. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol. 1995;(5 Suppl):71–75.
21. Xu HB, Fang L, Hu ZC, et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 2012;200(2–3):1054–1057.
22. Mayoral-Mariles A, Cruz-Revilla C, Vega-Manriquez X, et al. Plasma amino acid levels discriminate between control subjects and mildly depressed elderly women. Arch Med Res. 2012;43(5):375–382.
23. Lu YR, Fu XY, Shi LG, et al. Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder. BMC Psychiatry. 2014;14:123.
24. Hashimoto K, Yoshida T, Ishikawa M, et al. Increased serum levels of serine enantiomers in patients with depression. Acta Neuropsychiatr. 2016;28(3):173–178.
25. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007;62(11):1310–1316.
26. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61(7):705–713.
27. Arnone D, Mumuni AN, Jauhar S, et al. Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: meta-analysis of absolute prefrontal neuro-metabolic concentrations. Eur Neuropsychopharmacol. 2015;25(8):1109–1117.
28. Levine J, Panchalingam K, Rapoport A, et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47(7): 586–593.
29. Hashimoto K, Bruno D, Nierenberg J, et al. Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Transl Psychiatry. 2016;6:e744.
30. Frye MA, Tsai GE, Huggins T, et al. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2007; 61(10):162–166.
31. Garakani A, Martinez JM, Yehuda R, et al. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J Affect Disord. 2013;146(2):262–265.
32. Nishi A, Numata S, Tajima A, et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. 2014;40(5): 1154–1163.
33. Tomioka Y, Numata S, Kinoshita M, et al. Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis. J Psychiatry Neurosci. 2018;43(2):170053.
34. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
35. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
36. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
37. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–1157.
38. Shulman Y, Grant S, Seres P, et al. The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci. 2006;31(6):406–410.